The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The endorsement follows overwhelming support for the share swap preceding the merger,
The protections extend through at least 2035, with the potential for further extensions
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Launches advanced bone density systems in India & Dubai
Subscribe To Our Newsletter & Stay Updated
